FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127283911> ?p ?o ?g. }

• W2127283911 endingPage "19" @default.
• W2127283911 startingPage "7" @default.
• W2127283911 abstract "Study Objective To determine the impact of primary prophylactic colony-stimulating factor (CSF) use on febrile neutropenia in a large patient population receiving contemporary chemotherapy regimens to treat breast cancer, colorectal cancer, or non–small cell lung cancer (NSCLC). Design Retrospective claims analysis. Data Sources The Surveillance, Epidemiology, and End Results (SEER)-Puget Sound cancer registry and insurance claims records. Patients A total of 2728 patients aged 25 years or older who received a diagnosis of breast cancer (998 patients), colorectal cancer (688 patients), or NSCLC (1042 patients) between January 1, 2002, and December 31, 2005, and received chemotherapy. Measurements and Main Results Initial chemotherapy regimen, CSF use (filgrastim or pegfilgrastim), and febrile neutropenia events were evaluated after the first chemotherapy administration. Subsequently, febrile neutropenia rates in patients receiving primary prophylactic CSF were compared with febrile neutropenia rates in patients receiving CSF in settings other than primary prophylaxis or not at all. The impact of primary prophylactic CSF could not be assessed for patients with colorectal cancer or NSCLC because only 1 and 18 febrile neutropenia events, respectively, occurred in those receiving primary prophylactic CSF. Of the 998 patients with breast cancer, 72 (7.2%) experienced febrile neutropenia, 28 of whom received primary prophylactic CSF. In the patients with breast cancer, we observed that primary prophylactic CSF use was associated with reduced febrile neutropenia rates; however, the analysis may have been confounded by unmeasured factors associated with febrile neutropenia. Conclusion The impact of primary prophylactic CSFs on febrile neutropenia rates could not be demonstrated. Given the substantive cost of CSFs to pharmacy budgets, there are numerous opportunities for pharmacists to optimize CSF use. Research studies are needed to evaluate if guideline-directed prescribing of primary prophylactic CSFs can improve clinical outcomes." @default.
• W2127283911 created "2016-06-24" @default.
• W2127283911 creator A5001790380 @default.
• W2127283911 creator A5016058865 @default.
• W2127283911 creator A5024123937 @default.
• W2127283911 creator A5032325756 @default.
• W2127283911 creator A5037856690 @default.
• W2127283911 creator A5046666180 @default.
• W2127283911 creator A5046985026 @default.
• W2127283911 date "2012-01-01" @default.
• W2127283911 modified "2023-10-17" @default.
• W2127283911 title "Colony-Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non-Small Cell Lung Cancer Who Were Receiving Chemotherapy" @default.
• W2127283911 cites W1561052955 @default.
• W2127283911 cites W1828514487 @default.
• W2127283911 cites W1935885922 @default.
• W2127283911 cites W1980522764 @default.
• W2127283911 cites W1982414783 @default.
• W2127283911 cites W1989190276 @default.
• W2127283911 cites W1994787814 @default.
• W2127283911 cites W2005747223 @default.
• W2127283911 cites W2012539941 @default.
• W2127283911 cites W2032545981 @default.
• W2127283911 cites W2037139573 @default.
• W2127283911 cites W2037339308 @default.
• W2127283911 cites W2053519484 @default.
• W2127283911 cites W2068470820 @default.
• W2127283911 cites W2083336892 @default.
• W2127283911 cites W2091552760 @default.
• W2127283911 cites W2096334407 @default.
• W2127283911 cites W2099072173 @default.
• W2127283911 cites W2100440978 @default.
• W2127283911 cites W2101760255 @default.
• W2127283911 cites W2102273204 @default.
• W2127283911 cites W2102621753 @default.
• W2127283911 cites W2105304787 @default.
• W2127283911 cites W2105347888 @default.
• W2127283911 cites W2105550105 @default.
• W2127283911 cites W2105872767 @default.
• W2127283911 cites W2108752757 @default.
• W2127283911 cites W2108912949 @default.
• W2127283911 cites W2115432999 @default.
• W2127283911 cites W2120388840 @default.
• W2127283911 cites W2125835228 @default.
• W2127283911 cites W2128403792 @default.
• W2127283911 cites W2134055831 @default.
• W2127283911 cites W2134915662 @default.
• W2127283911 cites W2135255811 @default.
• W2127283911 cites W2140411476 @default.
• W2127283911 cites W2140626944 @default.
• W2127283911 cites W2142195688 @default.
• W2127283911 cites W2146161922 @default.
• W2127283911 cites W2146793261 @default.
• W2127283911 cites W2152755651 @default.
• W2127283911 cites W2156102434 @default.
• W2127283911 cites W2163351051 @default.
• W2127283911 cites W2169203358 @default.
• W2127283911 cites W2171232394 @default.
• W2127283911 cites W2217407321 @default.
• W2127283911 cites W2258823846 @default.
• W2127283911 cites W2086188072 @default.
• W2127283911 doi "https://doi.org/10.1002/phar.1008" @default.
• W2127283911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22392824" @default.
• W2127283911 hasPublicationYear "2012" @default.
• W2127283911 type Work @default.
• W2127283911 sameAs 2127283911 @default.
• W2127283911 citedByCount "13" @default.
• W2127283911 countsByYear W21272839112013 @default.
• W2127283911 countsByYear W21272839112014 @default.
• W2127283911 countsByYear W21272839112015 @default.
• W2127283911 countsByYear W21272839112016 @default.
• W2127283911 countsByYear W21272839112017 @default.
• W2127283911 countsByYear W21272839112018 @default.
• W2127283911 countsByYear W21272839112019 @default.
• W2127283911 countsByYear W21272839112022 @default.
• W2127283911 crossrefType "journal-article" @default.
• W2127283911 hasAuthorship W2127283911A5001790380 @default.
• W2127283911 hasAuthorship W2127283911A5016058865 @default.
• W2127283911 hasAuthorship W2127283911A5024123937 @default.
• W2127283911 hasAuthorship W2127283911A5032325756 @default.
• W2127283911 hasAuthorship W2127283911A5037856690 @default.
• W2127283911 hasAuthorship W2127283911A5046666180 @default.
• W2127283911 hasAuthorship W2127283911A5046985026 @default.
• W2127283911 hasConcept C121608353 @default.
• W2127283911 hasConcept C126322002 @default.
• W2127283911 hasConcept C141071460 @default.
• W2127283911 hasConcept C143998085 @default.
• W2127283911 hasConcept C2776256026 @default.
• W2127283911 hasConcept C2776694085 @default.
• W2127283911 hasConcept C2777063308 @default.
• W2127283911 hasConcept C2777767877 @default.
• W2127283911 hasConcept C2778336483 @default.
• W2127283911 hasConcept C2778850193 @default.
• W2127283911 hasConcept C2779171977 @default.
• W2127283911 hasConcept C526805850 @default.
• W2127283911 hasConcept C530470458 @default.
• W2127283911 hasConcept C71924100 @default.
• W2127283911 hasConceptScore W2127283911C121608353 @default.
• W2127283911 hasConceptScore W2127283911C126322002 @default.

• next